Mersana licenses anticancer analogue to Teva
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has acquired an exclusive licence to develop and commercialise Mersana Therapeutics' novel fumagillin analogue XMT-1107 for all indications globally, excluding Japan.